Lyell Immunopharma
Lyell Immunopharma Raises $425M in Series C
Lyell Immunopharma Raises $425M in Series C
Lyell Immunopharma has successfully raised $425M in a Series C at a $1.4B valuation led by GV, F-Prime Capital, Bain Capital Life Sciences, Patient Square Capital, Bristol Myers Squibb.
Company Overview
Lyell Immunopharma is a Biotech company headquartered in 201 Haskins Way, South San Francisco, CA 94080, founded in 2018 with 300+ employees.
T-cell reprogramming for solid tumors
Fundraising Details
- Amount Raised: $425M
- Round Type: Series C
- Valuation: $1.4B
- Date: 2024-03-09
- Investors: GV, F-Prime Capital, Bain Capital Life Sciences, Patient Square Capital, Bristol Myers Squibb
About Lyell Immunopharma
T-cell reprogramming for solid tumors The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: 201 Haskins Way, South San Francisco, CA 94080
- Founded: 2018
- Team Size: 300+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Lyell Immunopharma's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Lyell Immunopharma's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $1.4B valuation marks an important milestone for Lyell Immunopharma, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Lyell Immunopharma is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2024-03-09. For more information about Lyell Immunopharma, visit their headquarters at 201 Haskins Way, South San Francisco, CA 94080.
Company Info
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free